Based on 7 analysts giving stock ratings to Keros Therapeutics Inc in the past month.
In the current month, KROS has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KROS average Analyst price target in the last month is 19.800.
Based on analysts' estimates, KROS EPS is projected to reach -1.772 in FY2026Q4, following reported EPS of 0.712 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD 0.71, while Keros Therapeutics IncKROS's earnings per share (EPS) for the previous quarter was USD -1.45. EPS for the next quarter is expected at USD -1.77.